Amantadine influences cognitive processing in patients with multiple sclerosis.

Area of Science:

• Neuroscience
• Clinical Neurology
• Psychopharmacology

Background:

• Multiple sclerosis (MS) is a chronic neurological disease often accompanied by debilitating fatigue.
• Cognitive processing deficits are common in MS patients, impacting daily functioning.
• Amantadine is a medication sometimes used to manage MS symptoms, including fatigue.

Purpose of the Study:

• To investigate the effects of amantadine on cognitive processing in MS patients with fatigue.
• To utilize objective electrophysiological measures to assess cognitive function.
• To explore potential differences in treatment effects based on disease duration.

Main Methods:

• A double-blind, placebo-controlled, cross-over study design was used.
• Twenty-four MS patients with confirmed fatigue were included.
• Cognitive processing was assessed using behavioral (Reaction Time) and electrophysiological (Event Related Potentials: Selection Negativity, Lateralized Readiness Potential) measures.

Main Results:

• Amantadine treatment showed a significant difference in Event Related Potential (ERP) measures related to stimulus selection, with higher amplitudes observed.
• No significant differences in Reaction Time (RT) were found between amantadine and placebo.
• Patients with MS duration longer than 7 years demonstrated improved reaction speed and enhanced ERP amplitudes with amantadine, unlike those with shorter disease duration.

Conclusions:

• Amantadine may exert beneficial effects on early cognitive processing in multiple sclerosis patients.
• These positive effects appear to be more pronounced in patients with a longer disease duration.
• Electrophysiological measures provide sensitive indicators of amantadine's impact on cognitive function in MS.